Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy.
Diagnosis (Berl). 2021 Mar 1;8(4):413-420. doi: 10.1515/dx-2020-0161. Print 2021 Nov 25.
The COVID-19 pandemic will be remembered as one of the worst catastrophic events in human history. Unfortunately, no universally recognized effective therapeutic agents are currently available for the treatment of severe SARS-CoV-2 infection. In this context, the use of convalescent plasma from recovered COVID-19 patients has gained increasing interest thanks to the initially positive clinical reports. A number of mechanisms of action have been proposed for convalescent plasma, including direct neutralization and suppression of viremia, anti-inflammatory and immunomodulation effects and mitigation of the COVID-19-associated hypercoagulable state. These immune and non-immune mechanisms will be critically discussed in this narrative review.
新冠疫情将作为人类历史上最严重的灾难事件之一而被铭记。不幸的是,目前尚无被广泛认可的有效治疗药物可用于治疗严重的 SARS-CoV-2 感染。在这种情况下,得益于最初的积极临床报告,来自康复的 COVID-19 患者的恢复期血浆的使用引起了越来越多的关注。恢复期血浆具有多种作用机制,包括直接中和和抑制病毒血症、抗炎和免疫调节作用以及减轻 COVID-19 相关的高凝状态。在这篇叙述性综述中,将对这些免疫和非免疫机制进行批判性讨论。